Literature DB >> 34076402

New variants of SARS-CoV-2.

R Cantón, P De Lucas Ramos, A García-Botella, A García-Lledó, J Gómez-Pavón, J González Del Castillo, T Hernández-Sampelayo, M C Martín-Delgado, F J Martín Sánchez, M Martínez-Sellés, J M Molero García, S Moreno Guillén, F J Rodríguez-Artalejo, J Ruiz-Galiana, E Bouza1.   

Abstract

The emergence and spread of new variants of SARS-CoV-2 has produced enormous interest due to their possible implication in the improved transmissibility of the virus, their consequences in the individual evolution of the infection, as well as in the possible escape from the immunity generated by the current vaccines. The variants that attract most attention are those of public health concern, including B.1.1.7 (UK), P.1 (Brazilian) and B.1.351 (South African). This list is extended by the variants of interest that emerge and are expanding in certain countries but are found sporadically in others, such as B.1.427 and B.1.429 (Californians) or B.1.617 (Indian). Whole genome sequencing or strategies specifically targeting the spicule gene are used in the microbiology laboratories for characterization and detection. The number of infected individuals, the sanitary situation of each country, epidemiological measures and vaccination strategies influence its dispersion and new variants are expected to emerge. This emergence can only be avoided today by increasing the vaccinated population in all countries and by not relaxing epidemiological containment measures. It is not excluded that in the future it will be necessary to revaccinate against new variants. ©The Author 2021. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).

Entities:  

Keywords:  COVID-19; SARS-CoV2; vaccine resistance; viral variants

Year:  2021        PMID: 34076402     DOI: 10.37201/req/071.2021

Source DB:  PubMed          Journal:  Rev Esp Quimioter        ISSN: 0214-3429            Impact factor:   1.553


  20 in total

Review 1.  Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences.

Authors:  Reem Hoteit; Hadi M Yassine
Journal:  Vaccines (Basel)       Date:  2022-06-09

2.  The SARS-CoV-2 spike L452R-E484Q variant in the Indian B.1.617 strain showed significant reduction in the neutralization activity of immune sera.

Authors:  Gen Li; Zhongcheng Zhou; Peng Du; Meixing Yu; Ning Li; Xinxin Xiong; Hong Huang; Zhihai Liu; Qinjin Dai; Jie Zhu; Chengbin Guo; Shanyun Wu; Daniel T Baptista-Hon; Man Miao; Lam Wai Ming; Yong Wu; Fanxin Zeng; Charlotte L Zhang; Edward D Zhang; Haifeng Song; Jianghai Liu; Johnson Yiu-Nam Lau; Andy P Xiang; Kang Zhang
Journal:  Precis Clin Med       Date:  2021-07-30

Review 3.  Humoral and cellular immune response to severe acute respiratory syndrome coronavirus-2 vaccination in haemodialysis and kidney transplant patients.

Authors:  Joel Swai; Ming Gui; Mao Long; Zhu Wei; Zixuan Hu; Shaojun Liu
Journal:  Nephrology (Carlton)       Date:  2021-09-27       Impact factor: 2.358

4.  A scalable and highly immunogenic virus-like particle-based vaccine against SARS-CoV-2.

Authors:  Mona O Mohsen; Ina Balke; Simon Zinkhan; Villija Zeltina; Xuelan Liu; Xinyue Chang; Pascal S Krenger; Kevin Plattner; Zahra Gharailoo; Anne-Cathrine S Vogt; Gilles Augusto; Marianne Zwicker; Salony Roongta; Dominik A Rothen; Romano Josi; Joana J da Costa; Jan M Sobczak; Aleksandra Nonic; Lee-Anne Brand; Katja Nuss; Byron Martina; Daniel E Speiser; Thomas Kündig; Gary T Jennings; Senta M Walton; Monique Vogel; Andris Zeltins; Martin F Bachmann
Journal:  Allergy       Date:  2021-09-20       Impact factor: 14.710

Review 5.  Omicron - The new SARS-CoV-2 challenge?

Authors:  A Lino; M A Cardoso; P Martins-Lopes; H M R Gonçalves
Journal:  Rev Med Virol       Date:  2022-04-21       Impact factor: 11.043

6.  Imported SARS-COV-2 Variants of Concern Drove Spread of Infections Across Kenya During the Second Year of the Pandemic.

Authors:  Carolyne Nasimiyu; Damaris Matoke-Muhia; Gilbert K Rono; Eric Osoro; Daniel O Obado; J Milkah Mwangi; Nicholas Mwikwabe; Kelvin Thiongâ O; Jeanette Dawa; Isaac Ngere; John Gachohi; Samuel Kariuki; Evans Amukoye; Marianne Mureithi; Philip Ngere; Patrick Amoth; Ian Were; Lyndah Makayotto; Vishvanath Nene; Edward O Abworo; M Kariuki Njenga; Stephanie N Seifert; Samuel O Oyola
Journal:  medRxiv       Date:  2022-02-28

7.  The effectiveness of the Safety in Interventional Radiology (SIR) Shield in reducing droplet transmission and its effect on image quality and radiation dose.

Authors:  Shao Jin Ong; Gopinathan Anil; Koon Liang Chia; Deborah Khoo; Joseph Kt Lee; Priscilla Xh Chen; Teddy M Nares; Calvin J Koh; Peijing Su; Cunli Yang; Pavel Singh; Prapul C Rajendran; Timothy Fotheringham; Swee T Quek; Ian Renfrew
Journal:  Br J Radiol       Date:  2021-10-21       Impact factor: 3.039

8.  Preclinical immunological evaluation of an intradermal heterologous vaccine against SARS-CoV-2 variants.

Authors:  Shengtao Fan; Kang Xiao; Dandan Li; Heng Zhao; Jingjing Zhang; Li Yu; Penglan Chang; Shuangli Zhu; Xingli Xu; Yun Liao; Tianjiao Ji; Guorun Jiang; Dongmei Yan; Fengyuan Zeng; Suqin Duan; Baicheng Xia; Lichun Wang; Fengmei Yang; Zhanlong He; Yang Song; Pingfang Cui; Xiaolei Li; Yaxing Zhang; Bangyi Zheng; Ying Zhang; Wenbo Xu; Qihan Li
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 7.163

9.  The Disease Severity and Clinical Outcomes of the SARS-CoV-2 Variants of Concern.

Authors:  Lixin Lin; Ying Liu; Xiujuan Tang; Daihai He
Journal:  Front Public Health       Date:  2021-11-30

10.  Nursing strategic pillars to enhance nursing preparedness and response to COVID-19 pandemic at a tertiary care hospital in Saudi Arabia.

Authors:  Nabeeha Tashkandi; Maha Aljuaid; Theolinda McKerry; John Alchin; Laura Taylor; Elmer J Catangui; Rana Mulla; Suwarnnah Sinnappan; Georges Nammour; Aiman El-Saed; Majid M Alshamrani
Journal:  J Infect Public Health       Date:  2021-07-02       Impact factor: 7.537

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.